documents: FDA-2026-D-11783-0002
Data license: Public Domain (U.S. Government data) · Data source: Regulations.gov API (General Services Administration)
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | comment_end_datetime | perpetual_docket | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2026-D-11783-0002 | FDA | FDA-2026-D-11783 | Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry | Other | Guidance | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-11-27 | 2026-11-28 04:59:59 | 0 | 2026-11-22 10:00:37 | 1 | 0 | 09000064b96a45c1 |